Market Access

Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
 

Pfizer and AstraZeneca a Marriage Not to Be – Yet?

Contributor: Stephen Archer
Posted: 8/19/2014

Pfizer and AstraZeneca a Marriage Not to Be – Yet? - Stephen Archer

Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success in delivering the anticipated benefits is not good. Full Article »


Events related to this topic:

Preventing Type 2 Diabetes in the MENA Region

Contributor: Andrea Charles
Posted: 12/20/2011


Preventing Type 2 Diabetes in the MENA Region - Andrea Charles

Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview diabetes expert Professor Peter Schwarz, talks about the alarming growth of diabetes in the MENA region and strategies for prevention and management. Full Podcast »


Events related to this topic:

New Cardiovascular Drug Bucks Competitive Oncology-Only Trend in UK Early Access to Medicines Scheme - Dr Steven Bradshaw & Dr David Carr

One year on since the launch of the UK's Early Access to Medicines Scheme (EAMS), Novartis’ investigational heart failure drug LCZ696 (sacubitril/valsartan) has become the fifth therapy to be awarded a 'promising innovative medicine' (PIM) designation. Significantly for health technology manufacturers, LCZ696 is the first non-oncology therapy to receive a PIM, which, as Pharma IQ columnists Dr Steven Bradshaw and Dr David Carr discuss, is an important step for broadening early access to a wider range of medicines. Full Column »


Events related to this topic:

Early Access Programmes: EU Compliance Handbook

The increased market awareness for drugs targeting rare and life-threatening diseases has coincided with a rise in the number of patients requesting early access to these medicines. To meet the demand, an increasing number of pharmaceutical and biotechnology companies are deciding to develop early access programmes. However, navigating the nuances and complexities of these programmes has proven to be a resource draining task and companies are looking to develop standards and streamline their processes. Full Whitepaper »


Events related to this topic:



Advertise With Us

Join the Pharmas IQ Community